文献速递肾小球疾病

膜性肾病:2021核心教程

Membranous Nephropathy: Core Curriculum 2021.
PubMed 文献 · Am J Kidney Dis · 2021-01-21

膜性肾病是成人更常见的肾病综合征病因,近十年对其认识与管理快速演变。靶抗原(如PLA2R、THSD7A、NELL-1、SEMA3B)的发现支持更精准的分子诊断,监测循环自身抗体为疾病监测与免疫抑制决策提供新视角。利妥昔单抗的观察性及随机对照试验使其成为原发性膜性肾病治疗的前沿选择。

要点

  • 识别靶抗原可实现膜性肾病的精准分子诊断。
  • 监测循环自身抗体有助于疾病监测与免疫抑制决策。
  • 利妥昔单抗已成为原发性膜性肾病治疗的前沿选择。

核心结论

  • 膜性肾病的诊疗已因靶抗原识别和自身抗体监测而更加精准。
  • 利妥昔单抗在观察性及随机对照试验支持下成为原发性膜性肾病治疗前沿。

研究设计与样本

  • 本文为Core Curriculum综述,讨论原发性与继发性膜性肾病的典型特征、靶抗原、免疫与临床病程关系及现代管理。

主要发现

  • 膜性肾病是成人比儿童更常见的肾病综合征病因。
  • 靶抗原包括磷脂酶A2受体、THSD7A、NELL-1和SEMA3B。
  • 历史上免疫抑制以烷化剂联合糖皮质激素或钙调神经磷酸酶抑制剂方案为主。

关键数值与推荐

  • 靶抗原包括磷脂酶A2受体、含凝血酶敏感蛋白1结构域7A、神经表皮生长因子样1和semaphorin-3B。
  • 治疗选择包括支持治疗或基于复合参数的免疫抑制治疗。

临床怎么用

  • 临床可依据靶抗原和循环自身抗体监测指导膜性肾病的诊断与免疫抑制决策。
  • 原发性膜性肾病可考虑利妥昔单抗作为治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The understanding and management of membranous nephropathy, a common cause of nephrotic syndrome that is more frequently encountered in adults than in children, has rapidly evolved over the past decade. Identification of target antigens has allowed for more precise molecular diagnoses, and the ability to monitor circulating autoantibodies has added a new vantage point in terms of disease monitoring and decisions about immunosuppression. Although immunosuppression with alkylating agents combined with corticosteroids, or with calcineurin inhibitor-based regimens, has been the historical mainstay of treatment, observational and now randomized controlled trials with the B-cell-depleting agent rituximab have moved this agent to the forefront of therapy for primary membranous nephropathy. In this Core Curriculum, we discuss the typical features of primary and secondary disease; highlight the target antigens such as the phospholipase A2 receptor, thrombospondin type 1 domain-containing 7A, neural epidermal growth factor-like 1, and semaphorin-3B; describe the relationship between the immunologic and clinical courses of disease; and review modern management with supportive care or immunosuppressive treatment based on these composite parameters.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Alsharhan L, Beck LH. Membranous Nephropathy: Core Curriculum 2021. Am J Kidney Dis. 2021. PMID: 33487481. doi:10.1053/j.ajkd.2020.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。